Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. Q3 2026 Earnings Recap

MIST Q3 2026 Published November 14, 2026

Get alerts when MIST reports next quarter

Set up alerts — free

Milestone shares fell 20.6% after earnings, as investors likely focused on the gap between launch growth and the company’s need to cut costs: CARDAMYST prescriptions rose 50% quarter over quarter, but Milestone is reducing operating expenses by about 30% and restructuring its commercial organization. The transcript does not provide a revised sales outlook; the cost measures and leadership departures suggest the launch has yet to support the prior operating structure.

Earnings Per Share Beat
$-0.18 vs $-0.22 est.
+16.6% surprise
Revenue Beat
2963000 vs 1000000 est.
+196.3% surprise

Market Reaction

Post-Earnings -20.63%

See MIST alongside your other holdings

Add to your portfolio — free

Key Takeaways

  • CARDAMYST generated approximately 1,800 prescriptions in Q3, up 50% from Q2; cumulative prescriptions since launch reached approximately 3,400.
  • About 750 unique healthcare providers prescribed the drug in Q3, a 16% increase from Q2; cumulative prescribers reached approximately 1,600.
  • Formulary coverage rose to approximately two-thirds of commercially covered lives, from about 50% reported on the prior call.
  • Milestone expects cost measures to reduce operating expenses by approximately 30%, with implementation targeted for completion by Q1 2027; it expects about $2 million in one-time charges.
  • The company said the measures and an extended payment-in-kind interest period are expected to extend cash runway into late 2028, through the anticipated ReVeRA-301 Phase III readout in the second half of 2028.
This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MIST on AllInvestView.

Get the Full Picture on MIST

Track Milestone Pharmaceuticals Inc. in your portfolio with real-time analytics, dividend tracking, and more.

View MIST Analysis